Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05836987 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Study acronym: REACT-AF
StatusRecruiting
PhasePhase 3
Started2023-07-13
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 67 record versions are listed below. See every version on ClinicalTrials.gov ↗

2026-08-24
Study Status, Contacts/Locations v66
Study sitesdetails revised at 1 of 93 sites
2026-08-18
Study Status, Contacts/Locations v65
Study sitescontacts updated at 1 of 93 sites
2026-04-07
Study Status, Contacts/Locations v64
Study sites91→93
2026-03-30
Study Status, Contacts/Locations v63
Study sitesdetails revised at 1 of 91 sites
2026-02-16
Study Status, Contacts/Locations v62
Study sitesdetails revised at 1 of 91 sites
Show 45 earlier versions
2026-01-16
Study Status, Contacts/Locations v61
Study sitesdetails revised at 1 of 91 sites
2026-01-09
Study Status, Contacts/Locations v60
Study sitesdetails revised at 1 of 91 sites
2025-12-04
Study Status, Sponsor/Collaborators, Contacts/Locations v59
Study sites90→91
Collaborators1 to 2 entries
Northwestern University
2025-11-17
Study Status, Contacts/Locations v58
Study sites85→90
2025-10-27
Study Status, Contacts/Locations v57
Study sites84→85
2025-09-11
Study Status, Contacts/Locations v56
Study sitesdetails revised at 1 of 84 sites
2025-08-07
Study Status, Contacts/Locations v55
Study sitesdetails revised at 1 of 84 sites
2025-07-01
Study Status, Contacts/Locations v54
Re-verified, no change to tracked fields
2025-04-14
Study Status, Contacts/Locations v53
Study sitescontacts updated at 1 of 84 sites
2025-03-01
Study Status, Contacts/Locations v52
Study sitesdetails revised at 3 of 84 sites
2024-11-14
Study Status, Contacts/Locations v51
Study sitesdetails revised at 1 of 84 sites
2024-10-31
Study Status, Contacts/Locations v50
Study sitesdetails revised at 2 of 84 sites
2024-10-15
Study Status, Contacts/Locations v49
Study sites77→84
2024-07-04
Study Status, Contacts/Locations v48
Study sitesdetails revised at 1 of 77 sites
2024-06-25
Study Status, Contacts/Locations v47
Study sitescontacts updated at 1 of 77 sites
2024-06-03
Study Status, Eligibility v46
Eligibility criteria+383 characters
[...] omen without prior stroke or Transient Ischemic Attack (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs a [...] ble to comply with the protocol, including: Possession of a smartwatchsmart watch-compatible smartphonesmart phone (iPhone that supports the latest shipping iOS) with a cellula [...] [...]
2024-05-31
Study Status, Study Description, Eligibility v45
Eligibility criteria+208 characters
Inclusion Criteria: Male or female, 22-85 years of age. English speaking participants*. DocumentedSpanish-only historyspeakers may be included in the future at select sites appropriately translated. History of symptomaticnon-permanent oratrial asymptomatic paroxysmal or persistent AF. The duration of AF must have been > 30 seconds as documented by an external monitor or present on 12-lead ECGfibrillation. CHA2DS2-VASC score of 1-4 for men and 2-4 for women without prior stroke or Transient Ischemic Attack (TIA)**. Congestive heart failure defined as: The presence of signs and symptoms of eithe [...] [...]
Study description+23 characters
[...] moderate risk of stroke measured by CHA2DS2-VASc score 1-4 for men, 2-4 for women (which stands for Congestive heart failure, Hypertension, Ag [...]
2024-05-14
Study Status, Contacts/Locations v44
Study sites76→77
2024-04-18
Study Status, Contacts/Locations v43
Study sitesdetails revised at 1 of 76 sites
2024-04-16
Study Status, Contacts/Locations v42
Study sitesdetails revised at 1 of 76 sites
2024-03-12
Study Status, Contacts/Locations v41
Study sitesdetails revised at 1 of 76 sites
2024-03-08
Study Status, Contacts/Locations v40
Study sitesdetails revised at 4 of 76 sites
2024-03-05
Study Status, Contacts/Locations v39
Study sites69→76
2024-02-29
Study Status, Contacts/Locations v38
Study sitesdetails revised at 1 of 69 sites
2024-02-26
Study Status, Contacts/Locations v37
Study sitesdetails revised at 8 of 69 sites
2024-01-25
Study Status, Contacts/Locations v36
Study sitesdetails revised at 2 of 69 sites
2024-01-02
Study Status, Contacts/Locations v35
Study sites66→69
2023-12-18
Study Status, Contacts/Locations v34
Study sitesdetails revised at 2 of 66 sites
2023-12-13
Study Status, Contacts/Locations v33
Study sites66 entries, revised
NYU GrossmanLangone School of MedicineHealth
2023-12-11
Study Status, Contacts/Locations v32
Study sitesdetails revised at 2 of 66 sites
2023-12-06
Study Status, Contacts/Locations v31
Study sitesdetails revised at 1 of 66 sites
2023-11-30
Study Status, Contacts/Locations v30
Study sitesdetails revised at 2 of 66 sites
2023-11-27
Study Status, Contacts/Locations v29
Study sites40→66
2023-10-18
Study Status, Contacts/Locations v28
Study sitesdetails revised at 1 of 40 sites
2023-10-03
Study Status, Contacts/Locations v27
Re-verified, no change to tracked fields
2023-09-22
Study Status, Contacts/Locations v26
Study sites39→40
2023-09-13
Study Status, Contacts/Locations v25
Study sitesdetails revised at 1 of 39 sites
2023-09-07
Study Status, Contacts/Locations v24
Study sitesdetails revised at 2 of 39 sites
2023-09-07
Study Status, Contacts/Locations v23
Study sitesdetails revised at 1 of 39 sites
2023-09-01
Study Status, Contacts/Locations v22
Study sitesdetails revised at 1 of 39 sites
2023-08-30
Study Status, Contacts/Locations v21
Study sites38→39
2023-08-28
Study Status, Contacts/Locations v20
Study sitesdetails revised at 3 of 38 sites
2023-08-21
Study Status, Contacts/Locations v19
Study sitesdetails revised at 1 of 38 sites
2023-08-15
Study Status, Contacts/Locations v18
Study sitesdetails revised at 1 of 38 sites
2023-08-10
Study Status, Contacts/Locations v17
Study sitesdetails revised at 1 of 38 sites
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Trial Details
NCT Number NCT05836987
Lead Sponsor Johns Hopkins University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Northwestern University
Conditions Atrial Fibrillation
Enrollment 5,350 participants
Start Date 2023-07-13
Primary Completion 2029-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-30